Gene · 28402
Papers3,091
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 3,091
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Hepatitis Virus-associated Non-hodgkin Lymphoma: Pathogenesis and Treatment Strategies. | J Clin Transl Hepatol | 2023 | 37577221 | PubTator, text mining | PubMed |
| Role of microRNAs in Chronic Lymphocytic Leukemia. | Int J Mol Sci | 2023 | 37569845 | PubTator, text mining | PubMed |
| First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era. | Cancers (Basel) | 2023 | 37568676 | PubTator, text mining | PubMed |
| Specific attributes of the VL domain influence both the structure and structural variability of CDR-H3 through steric effects. | Front Immunol | 2023 | 37564639 | PubTator, text mining | PubMed |
| SF3B1 mutation-mediated sensitization to H3B-8800 splicing inhibitor in chronic lymphocytic leukemia. | Life Sci Alliance | 2023 | 37562845 | PubTator, text mining | PubMed |
| Clonal composition and differentiation stage of human CD30+ B cells in reactive lymph nodes. | Front Immunol | 2023 | 37559724 | PubTator, text mining | PubMed |
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort. | Blood Cancer J | 2023 | 37558684 | PubTator, text mining | PubMed |
| Molecular characteristics in Chinese with chronic lymphocytic leukemia by next-generation sequencing: A single-center retrospective analysis. | Int J Lab Hematol | 2023 | 37551448 | PubTator, text mining | PubMed |
| [CAR-T cell combined with PD-1 inhibitor in the treatment of high-risk chronic lymphocytic leukemia with Richter's transformation: two cases report and literature review]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | 37550195 | PubTator, text mining | PubMed |
| IGHV allele similarity clustering improves genotype inference from adaptive immune receptor repertoire sequencing data. | Nucleic Acids Res | 2023 | 37548401 | PubTator, text mining | PubMed |
| Hairy cell leukaemia with unusual BRAF mutations. | J Cell Mol Med | 2023 | 37530550 | PubTator, text mining | PubMed |
| Evaluation of the CLL-IPI and IPS-E Prognostic Indices in a Young Middle Eastern Population with Chronic Lymphocytic Leukemia: A Retrospective Analysis at the Kuwait Cancer Control Center. | Med Princ Pract | 2023 | 37517397 | PubTator, text mining | PubMed |
| The Role of Cholesterol in Chronic Lymphocytic Leukemia Development and Pathogenesis. | Metabolites | 2023 | 37512506 | PubTator, text mining | PubMed |
| SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia. | Int J Mol Sci | 2023 | 37511096 | PubTator, text mining | PubMed |
| Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. | Cancers (Basel) | 2023 | 37509398 | PubTator, text mining | PubMed |
| Integrated Multi-Omic Analysis Reveals Immunosuppressive Phenotype Associated with Poor Outcomes in High-Grade Serous Ovarian Cancer. | Cancers (Basel) | 2023 | 37509311 | PubTator, text mining | PubMed |
| Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia. | Cancers (Basel) | 2023 | 37509309 | PubTator, text mining | PubMed |
| Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade. | Curr Oncol | 2023 | 37504332 | PubTator, text mining | PubMed |
| The Nanomechanical Properties of CLL Cells Are Linked to the Actin Cytoskeleton and Are a Potential Target of BTK Inhibitors. | Hemasphere | 2023 | 37492437 | PubTator, text mining | PubMed |
| Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis. | Leukemia | 2023 | 37479761 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/28402/papers?page=15